391 related articles for article (PubMed ID: 33489450)
1. Bortezomib induced pulmonary toxicity: a case report and review of the literature.
Saglam B; Kalyon H; Ozbalak M; Ornek S; Keske S; Tabak L; Cakar N; Zeren H; Aytekin S; Bolukbasi Y; Ferhanoglu B
Am J Blood Res; 2020; 10(6):407-415. PubMed ID: 33489450
[TBL] [Abstract][Full Text] [Related]
2. Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.
Akosman C; Ordu C; Eroglu E; Oyan B
Am J Ther; 2015; 22(3):e88-92. PubMed ID: 24100255
[TBL] [Abstract][Full Text] [Related]
3. Pneumonitis associated with bortezomib in a patient with multiple myeloma.
Kars TU; Yaşkıran O; Çeneli Ö
J Oncol Pharm Pract; 2023 Jun; 29(4):1021-1024. PubMed ID: 36476141
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.
Li J; Chen S; Hu Y; Cai J
Oncol Lett; 2016 Mar; 11(3):2255-2260. PubMed ID: 26998158
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
7. [Successful steroid pulse therapy for COVID-19 associated respiratory failure initially mimicking bortezomib-induced lung injury].
Fujii T; Saito H; Ide S; Ohara S; Uchida T; Inoue M; Hagihara M; Kushimoto K; Nishiura M; Oashi A; Ochi J
Rinsho Ketsueki; 2021; 62(1):30-34. PubMed ID: 33551422
[TBL] [Abstract][Full Text] [Related]
8. Successfully non-surgical management of flail chest as first manifestation of multiple myeloma: A case report.
Muñoz-Bermúdez R; Abella E; Zuccarino F; Masclans JR; Nolla-Salas J
World J Crit Care Med; 2019 Sep; 8(5):82-86. PubMed ID: 31559147
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
10. A fatal case of bortezomib-induced lung toxicity in a young adult heart transplant recipient.
Frandsen EL; Otero J; Rutledge JC; Kemna MS; Albers EL; Hong BJ; Law YM; Friedland-Little JM
Pediatr Transplant; 2020 Feb; 24(1):e13628. PubMed ID: 31815325
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Yamaguchi T; Sasaki M; Itoh K
Jpn J Clin Oncol; 2012 Jul; 42(7):637-9. PubMed ID: 22628610
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Zuo W; Zhu X; Yang J; Mei Z; Deng M; Lin Q; Song Y; Yin Q
Medicine (Baltimore); 2017 Jan; 96(1):e5787. PubMed ID: 28072730
[TBL] [Abstract][Full Text] [Related]
13. Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone.
Yasui T; Shioyama W; Oboshi M; Nishikawa T; Kamada R; Oka T; Fujita M
J Cardiol Cases; 2020 May; 21(5):197-199. PubMed ID: 32373247
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.
Erath A; Patel DA; Hosack EA; Patanella JE; Ibach DM; Kassim AA
World J Oncol; 2020 Feb; 11(1):33-36. PubMed ID: 32095187
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
19. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.
Miyakoshi S; Kami M; Yuji K; Matsumura T; Takatoku M; Sasaki M; Narimatsu H; Fujii T; Kawabata M; Taniguchi S; Ozawa K; Oshimi K
Blood; 2006 May; 107(9):3492-4. PubMed ID: 16410442
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
